Amicus Therapeutics, Inc.

Historical 13F Holders

Symbol
FOLD
CUSIP
03152W109
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 03152W109 since 12/18/2024, largest first.

Filer % of Class Filed
BlackRock, Inc. 13G/A 7.4% 4/23/2025
Event 3/31/2025
Barclays PLC 13G 5.7% 5/14/2026
Event 3/31/2026
UBS Group AG 13G 5.5% 5/7/2026
Event 3/31/2026
Vanguard Capital Management LLC 13G 5.2% 4/29/2026
Event 3/31/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (8)
Avoro Capital Advisors LLC 13G/A
4.9% 11/14/2025
Event 9/30/2025
Redmile Group, LLC 13G/A
4.6% 2/14/2025
Event 12/31/2024
William Blair Investment Management, LLC 13G/A 3.4% 2/9/2026
Event 12/31/2025
Perceptive Advisors LLC 13G/A
2.4% 8/14/2025
Event 6/30/2025
Wellington Management Group LLP 13G/A
0.4% 2/10/2026
Event 12/31/2025
Glazer Capital, LLC 13G
0% 5/1/2026
Event 4/24/2026
Goldman Sachs Group Inc 13G/A
0% 8/12/2026
Event 6/30/2026
Vanguard Group Inc 13G/A 0% 3/26/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 2 797 $11.5 k
2026 Q1 308 333 M $4.81 B
2025 Q4 353 321 M $4.57 B
2025 Q3 313 314 M $2.48 B
2025 Q2 289 326 M $1.87 B
2025 Q1 308 313 M $2.56 B
2024 Q4 312 305 M $2.88 B
2024 Q3 312 323 M $3.45 B
2024 Q2 278 335 M $3.32 B
2024 Q1 274 357 M $4.21 B
2023 Q4 254 352 M $5.00 B
2023 Q3 255 299 M $3.64 B
2023 Q2 235 307 M $3.86 B
2023 Q1 242 298 M $3.30 B
2022 Q4 254 305 M $3.73 B
2022 Q3 243 308 M $3.21 B
2022 Q2 230 305 M $3.28 B
2022 Q1 237 304 M $2.88 B
2021 Q4 245 329 M $3.79 B
2021 Q3 263 293 M $2.80 B
2021 Q2 258 300 M $2.89 B
2021 Q1 287 299 M $2.97 B
2020 Q4 320 280 M $6.45 B
2020 Q3 278 278 M $3.93 B
2020 Q2 254 283 M $4.26 B
2020 Q1 228 288 M $2.66 B
2019 Q4 248 280 M $2.73 B
2019 Q3 231 279 M $2.24 B
2019 Q2 235 272 M $3.39 B
2019 Q1 232 258 M $3.50 B
2018 Q4 214 234 M $2.23 B
2018 Q3 234 237 M $2.87 B
2018 Q2 230 228 M $3.56 B
2018 Q1 235 227 M $3.42 B
2017 Q4 221 206 M $2.96 B
2017 Q3 229 198 M $2.99 B
2017 Q2 169 174 M $1.75 B
2017 Q1 158 175 M $1.25 B
2016 Q4 161 160 M $795 M
2016 Q3 154 148 M $1.10 B
2016 Q2 141 142 M $781 M
2016 Q1 151 140 M $1.18 B
2015 Q4 158 139 M $1.35 B
2015 Q3 165 146 M $2.00 B
2015 Q2 153 114 M $1.61 B
2015 Q1 138 82.3 M $892 M
2014 Q4 117 79.8 M $664 M
2014 Q3 105 47.0 M $280 M
2014 Q2 65 40.7 M $136 M
2014 Q1 72 38.3 M $79.2 M